|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/675 | (2006.01) |
| A61K 31/675 | (2013.01) | ||
| A61P 35/04 | (2006.01) | ||
| A61K 31/337 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 31/506 | (2013.01) | ||
| A61K 31/519 | (2006.01) | ||
| A61K 31/407 | (2013.01) | ||
| A61K 31/506 | (2006.01) | ||
| A61K 31/519 | (2013.01) | ||
| A61K 31/496 | (2006.01) | ||
| A61P 19/08 | (2018.01) | ||
| A61K 31/337 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 31/407 | (2006.01) | ||
| A61K 31/496 | (2013.01) |
| (11) | Patento numeris | 3914257 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 21754882.5 |
| Europos patento paraiškos padavimo data | 2021-04-01 | |
| (97) | Europos patento paraiškos paskelbimo data | 2021-12-01 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-12-27 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/CN2021/084970 |
| Data | 2021-04-01 |
| (87) | Numeris | WO 2021/204060 |
| Data | 2021-10-14 |
| (30) | Numeris | Data | Šalis |
| PCT/CN2020/084145 | 2020-04-10 | WO | |
| 202110344288 | 2021-03-31 | CN |
| (72) |
ZHAI, Yifan , CN
YANG, Dajun , CN
|
| (73) |
Ascentage Pharma (Suzhou) Co., Ltd. ,
Unit 701, Building B7, 218 Xinghu Street
Suzhou Industrial Park, Suzhou, Jiangsu 215000,
CN
Ascentage Pharma Group Corp Limited , 9/F., Wah Yuen Building 149 Queen's Road Central, Hong Kong 999077, CN |
| (54) | COMBINATION OF A BCL-2/BCL-XL INHIBITOR WITH OSIMERTINIB |
| COMBINATION OF A BCL-2/BCL-XL INHIBITOR WITH OSIMERTINIB |